Literature DB >> 8721539

Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases.

M D de Jong1, C A Boucher, G J Galasso, M S Hirsch, E R Kern, J M Lange, D D Richman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8721539     DOI： 10.1016/0166-3542(95)00910-8

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  5 in total

1.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues.

Authors:  J K Wong; C C Ignacio; F Torriani; D Havlir; N J Fitch; D D Richman
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 3.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 4.  Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.

Authors:  C M Perry; D Faulds
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

5.  Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies.

Authors:  M D de Jong; C A Boucher; D A Cooper; G J Galasso; B Gazzard; J M Lange; J S Montaner; D D Richman; H C Thomas
Journal:  Antiviral Res       Date:  1997-07       Impact factor: 5.970
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.